BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 23846499)

  • 1. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
    Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence.
    Caron M; Auclair M; Donadille B; Béréziat V; Guerci B; Laville M; Narbonne H; Bodemer C; Lascols O; Capeau J; Vigouroux C
    Cell Death Differ; 2007 Oct; 14(10):1759-67. PubMed ID: 17612587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks.
    Briand N; Guénantin AC; Jeziorowska D; Shah A; Mantecon M; Capel E; Garcia M; Oldenburg A; Paulsen J; Hulot JS; Vigouroux C; Collas P
    Hum Mol Genet; 2018 Apr; 27(8):1447-1459. PubMed ID: 29438482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation.
    Afonso P; Auclair M; Boccara F; Vantyghem MC; Katlama C; Capeau J; Vigouroux C; Caron-Debarle M
    Atherosclerosis; 2016 Feb; 245():200-11. PubMed ID: 26724531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy.
    Araújo-Vilar D; Lattanzi G; González-Méndez B; Costa-Freitas AT; Prieto D; Columbaro M; Mattioli E; Victoria B; Martínez-Sánchez N; Ramazanova A; Fraga M; Beiras A; Forteza J; Domínguez-Gerpe L; Calvo C; Lado-Abeal J
    J Med Genet; 2009 Jan; 46(1):40-8. PubMed ID: 18805829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulation of Fragile X-related protein 1 by the lipodystrophic lamin A p.R482W mutation elicits a myogenic gene expression program in preadipocytes.
    Oldenburg AR; Delbarre E; Thiede B; Vigouroux C; Collas P
    Hum Mol Genet; 2014 Mar; 23(5):1151-62. PubMed ID: 24108105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A homozygous mutation of prelamin-A preventing its farnesylation and maturation leads to a severe lipodystrophic phenotype: new insights into the pathogenicity of nonfarnesylated prelamin-A.
    Le Dour C; Schneebeli S; Bakiri F; Darcel F; Jacquemont ML; Maubert MA; Auclair M; Jeziorowska D; Reznik Y; Béréziat V; Capeau J; Lascols O; Vigouroux C
    J Clin Endocrinol Metab; 2011 May; 96(5):E856-62. PubMed ID: 21346069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy.
    Vadrot N; Duband-Goulet I; Cabet E; Attanda W; Barateau A; Vicart P; Gerbal F; Briand N; Vigouroux C; Oldenburg AR; Lund EG; Collas P; Buendia B
    Hum Mol Genet; 2015 Apr; 24(7):2096-109. PubMed ID: 25524705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LMNA missense mutations causing familial partial lipodystrophy do not lead to an accumulation of prelamin A.
    Tu Y; Sánchez-Iglesias S; Araújo-Vilar D; Fong LG; Young SG
    Nucleus; 2016 Sep; 7(5):512-521. PubMed ID: 27841971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A.
    Andre P; Schneebeli S; Vigouroux C; Lascols O; Schaaf M; Chevalier P
    Am Heart J; 2015 Apr; 169(4):587-93. PubMed ID: 25819867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The R439C mutation in LMNA causes lamin oligomerization and susceptibility to oxidative stress.
    Verstraeten VL; Caputo S; van Steensel MA; Duband-Goulet I; Zinn-Justin S; Kamps M; Kuijpers HJ; Ostlund C; Worman HJ; Briedé JJ; Le Dour C; Marcelis CL; van Geel M; Steijlen PM; van den Wijngaard A; Ramaekers FC; Broers JL
    J Cell Mol Med; 2009 May; 13(5):959-71. PubMed ID: 19220582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LMNA-linked lipodystrophies: from altered fat distribution to cellular alterations.
    Bidault G; Vatier C; Capeau J; Vigouroux C; Béréziat V
    Biochem Soc Trans; 2011 Dec; 39(6):1752-7. PubMed ID: 22103520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial partial lipodystrophy due to the LMNA R482W mutation with multinodular goitre, extrapyramidal syndrome and primary hyperaldosteronism.
    Vantyghem MC; Faivre-Defrance F; Marcelli-Tourvieille S; Fermon C; Evrard A; Bourdelle-Hego MF; Vigouroux C; Defebvre L; Delemer B; Wemeau JL
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):247-9. PubMed ID: 17524034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear envelope-related lipodystrophies.
    Guénantin AC; Briand N; Bidault G; Afonso P; Béréziat V; Vatier C; Lascols O; Caron-Debarle M; Capeau J; Vigouroux C
    Semin Cell Dev Biol; 2014 May; 29():148-57. PubMed ID: 24384368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
    Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.
    Araújo-Vilar D; Lado-Abeal J; Palos-Paz F; Lattanzi G; Bandín MA; Bellido D; Domínguez-Gerpe L; Calvo C; Pérez O; Ramazanova A; Martínez-Sánchez N; Victoria B; Costa-Freitas AT
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):61-8. PubMed ID: 18031308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism.
    Friesen M; Cowan CA
    Biochem Biophys Res Commun; 2018 Jan; 495(1):254-260. PubMed ID: 29108996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prelamin A-mediated nuclear envelope dynamics in normal and laminopathic cells.
    Lattanzi G
    Biochem Soc Trans; 2011 Dec; 39(6):1698-704. PubMed ID: 22103510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
    Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prelamin A accumulation in endothelial cells induces premature senescence and functional impairment.
    Bonello-Palot N; Simoncini S; Robert S; Bourgeois P; Sabatier F; Levy N; Dignat-George F; Badens C
    Atherosclerosis; 2014 Nov; 237(1):45-52. PubMed ID: 25200614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.